Frequently asked questions in drug combinations and the mass-action law-based answers
- 1 September 2014
- journal article
- Published by Elsevier BV in Synergy
- Vol. 1 (1), 3-21
- https://doi.org/10.1016/j.synres.2014.07.003
Abstract
No abstract availableThis publication has 55 references indexed in Scilit:
- Synthetic Lethal Screen of an EGFR-Centered Network to Improve Targeted TherapiesScience Signaling, 2010
- Nuclear Phospho-Akt Increase Predicts Synergy of PI3K Inhibition and Doxorubicin in Breast and Ovarian CancerScience Translational Medicine, 2010
- Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitorsNature, 2010
- Combination chemical geneticsNature Chemical Biology, 2008
- 90-kDa Heat Shock Protein Inhibition Abrogates the Topoisomerase I Poison-Induced G2/M Checkpoint in p53-Null Tumor Cells by Depleting Chk1 and Wee1Molecular Pharmacology, 2008
- Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugsNature Medicine, 2008
- Multicomponent therapeutics for networked systemsNature Reviews Drug Discovery, 2005
- On the determination of availability of ligand binding sites in steady-state systemsJournal of Theoretical Biology, 1977
- Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligandsJournal of Theoretical Biology, 1976
- Combinatorial analysis of multiple substrate—multiple product enzyme reactionsJournal of Theoretical Biology, 1972